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Background: Antibodies raised against selected antigens over-expressed at the cell surface of malignant cells have
been chemically conjugated to protein toxin domains to obtain immunotoxins (ITs) able to selectively kill cancer
cells. Since latest generation immunotoxins are composed of a toxic domain genetically fused to antibody fragment(s)
which confer on the IT target selective specificity, we rescued from the hydridoma 4KB128, a recombinant single-chain
variable fragment (scFv) targeting CD22, a marker antigen expressed by B-lineage leukaemias and lymphomas. We
constructed several ITs using two enzymatic toxins both able to block protein translation, one of bacterial origin (a
truncated version of Pseudomonas exotoxin A, PE40) endowed with EF-2 ADP-ribosylation activity, the other being the
plant ribosome-inactivating protein saporin, able to specifically depurinate 23/26/28S ribosomal RNA. PE40 was selected
because it has been widely used for the construction of recombinant ITs that have already undergone evaluation in
clinical trials. Saporin has also been evaluated clinically and has recently been expressed successfully at high levels in a
Pichia pastoris expression system. The aim of the present study was to evaluate optimal microbial expression of various
IT formats.
Results: An anti-CD22 scFv termed 4KB was obtained which showed the expected binding activity which was also
internalized by CD22+ target cells and was also competed for by the parental monoclonal CD22 antibody. Several
fusion constructs were designed and expressed either in E. coli or in Pichia pastoris and the resulting fusion proteins
affinity-purified. Protein synthesis inhibition assays were performed on CD22+ human Daudi cells and showed that the
selected ITs were active, having IC50 values (concentration inhibiting protein synthesis by 50% relative to controls) in
the nanomolar range.
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Conclusions: We undertook a systematic comparison between the performance of the different fusion constructs,
with respect to yields in E. coli or P. pastoris expression systems and also with regard to each constructs specific
killing efficacy. Our results confirm that E. coli is the system of choice for the expression of recombinant fusion toxins
of bacterial origin whereas we further demonstrate that saporin-based ITs are best expressed and recovered from
P. pastoris cultures after yeast codon-usage optimization.
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expression systemsBackground
Over a century ago Paul Ehrlich formulated a new idea
in medicine, the “magic bullet” concept, in which a drug
would be selectively directed against a pathogen/cellular
target and which would therefore be innocuous to the
surrounding healthy tissues. This concept was later real-
ized by the discovery of monoclonal antibodies, provid-
ing us with molecules endowed with antigen-specific
binding capability [1] thus opening the way for the first
generation of immunotoxins (ITs) constructed with whole
antibodies conjugated to chemically modified toxic do-
mains. These first generation ITs were created by cross-
linking monoclonal antibodies directed against marker
antigens overexpressed on the tumor cell surface to toxin
protein domains of choice, derived either from plants like
saporin or ricin A chain or as Diphtheria and Pseudo-
monas toxin domains, from bacteria. However, these type
of ITs possessed several weaknesses as follows: 1) hetero-
geneity among different batch preparations, 2) high im-
munogenicity and 3) safety issues and high costs for their
production under GMP conditions [2].
This led to the development of a new generation of re-
combinant chimeric molecules (for a review see [3-5])
which are not only easier to manipulate but which also
yield ITs endowed with consistent physico-chemical
properties. In particular, toxic enzymatic sequences can
be directly genetically fused to sequences encoding the
selected targeting domains (e.g. hormones, growth fac-
tors, antibody portions, including single-chain variable
fragments (scFv)). Additionally, toxin molecules can be
engineered to delete unwanted native cell-binding do-
mains while retaining those domains involved in cell
membrane translocating activity. Targeting domains
might also be further modified to enhance their cellular
specificity, binding affinity, etc.
Neoplastic B-cells arising in hematopoietic malignan-
cies frequently express at their surface the CD19 and
CD22 differentiation antigens. CD22 is not expressed by
any other normal tissue being restricted to only normal
and malignant B-cells making this a good candidate target
molecule for antibody-targeted therapies. A combination
of anti-CD19, −CD22, and -CD38-saporin ITs (3BIT cock-
tail) has been shown previously to cure severe combinedimmunodeficient mice xenografted with the human B-cell
lymphoma cell line Ramos, resulting in 100% disease-free
survivors at 300 days [6]. Several first generation anti-
CD22 ITs have been described in the past some chemically
conjugated to plant deglycosylated ricin A-chain [7] and
others to Pseudomonas Exotoxin A (PEA) that have
yielded encouraging results in vivo in animal models and
in clinical trials in humans [8]. However, due to some of
the above-mentioned limitations, development of fully re-
combinant anti-CD22 ITs is highly desirable for thera-
peutic use in humans. BL22 is a fusion protein derived
from the parental anti-CD22 RFB4 monoclonal antibody
formed between an anti-CD22 disulfide-stabilized anti-
body fragment (dsFv) and a shorter version of bacterial
PEA termed PE38. In 2001 results were reported of
complete remissions in a phase I trial for hairy cell
leukemia [9]. A next generation IT (High affinity BL22)
molecule, HA22 [3,10], incorporated a three amino acid
change in the antibody fragment to increase the binding
affinity for the target CD22 molecule and is currently
under clinical evaluation by NIH.
Single-chain fragment variable antibody fragments (scFv)
are recombinant molecules which can be derived from
phage display libraries [11] or alternatively from hybrid-
omas secreting whole murine antibodies by RT-PCR
amplification of the variable antibody domain sequences.
Although of murine origin, the scFv represent a less
immunogenic portion of the antibody molecule. Humani-
zation of murine scFv would further reduce their
immunogenicity and help to prevent neutralizing or
damaging immune responses following repeated admin-
istration to patients. Avoiding an immune response
against the toxic moiety is more problematical, but strat-
egies have been developed to minimize this and allow re-
peated administrations in vivo. For example, PE38, a
recombinant version of Pseudomonas Exotoxin A could
be de-immunized by deletions/substitution of the main
immunogenic residues [12-14]. Alternatively, fusion
toxins may be engineered using a weakly immunogenic
[15,16]; (Flavell et al., unpublished observations) toxin
such as saporin from Saponaria officinalis. Thus different
toxic portions could easily be swapped into chimeric
recombinant constructs, retaining the same targeting
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against the toxic moiety to be reduced and secondly to
provide the opportunity to swap in a different toxin do-
main whilst retaining the same target antigen specificity.
In the present study, we compared different constructs
containing the same recombinant anti-CD22 scFv fused
to two different toxin domains: PE40, a truncated ver-
sion of Pseudomonas exotoxin A, or saporin. Both were
expressed either in prokaryotic (i.e. E. coli, already de-
scribed for PE40-based IT [17]) or eukaryotic (i.e. Pichia
pastoris, already described for saporin [16]) microbial
hosts, in order to set-up the most appropriate conditions
for the rapid development of new anti-CD22 recombin-
ant ITs.
We made fusion proteins between an scFV derived
from a previously described anti-CD22 murine IgG1
antibody (4KB128, [18]) which formerly demonstrated
excellent targeting properties as a carrier of native seed-
derived saporin against a human B-cell lymphoma cell
line [6] and full length saporin or PE40 as the toxin
moiety.
Overall our results demonstrate that IT containing a
toxin moiety of bacterial origin are better expressed in
the E. coli host, while saporin-based ITs are best ex-
pressed in the P. pastoris system. The potency of the
resulting IT molecules obtained was comparable, with
the PE40-based IT showing a 5-fold higher cytotoxic ac-
tivity in some experiments.
Results and discussion
Rationale for the design of experiments
To date, bacterial and yeast host cells have been used to
produce RIPs or RIP-based ITs [19,20]. One common
problem faced during the production of recombinant
RIPs resides in their intrinsic toxicity toward the host ri-
bosomes. Toxin expression can be rapidly achieved in
bacteria and tightly regulated by employing specific E.
coli strains, to obtain satisfactory yields [21,22], but in
some cases the protein may accumulate inside the cell
as an insoluble fraction from which fully active RIP is
not easily recoverable. Endotoxin contamination to-
gether with inefficient folding of certain secretory target-
ing domains appear to be the main disadvantages of the
bacterial expression systems and this has prompted the
more recent development of eukaryotic expression sys-
tems. The methylotrophic yeast Pichia pastoris has been
demonstrated to be a suitable platform for the expression
of recombinant proteins, allowing protein post-translation
modifications and a several-fold yield improvement in
product [23]. Recombinant DT-based IT fusions has been
successfully expressed in P. pastoris, in the GS115 strain
that was found to be particularly tolerant to this bacterial
toxin [24]. Toxicity was most likely prevented through
rapid and efficient secretion of the toxin into the culturemedium, allowing for easier downstream purification and
production scale up. On the other hand, yeast expression
systems for the production of toxins takes longer than for
bacterial expression systems and concomitantly secreted
or membrane-bound enzymes can proteolytically cleave
the expressed recombinant proteins. In this regard the
two toxic domains we used in the production of fusion ITs
match some of the requirements, since Pseudomonas exo-
toxin A has been successfully used to construct recombin-
ant ITs expressed in E. coli [17] in the truncated PE38
version, easily recovered from inclusion bodies, while
saporin has been expressed as both free toxin or fusion IT
[16] by our group in Pichia pastoris and is easily purified
from the culture medium. In the latter case we noticed a
strong influence of the antibody moiety on the stability
and intracellular processing of the recombinant IT in the
eukaryotic system. Taking these aspects into consideration
we decided to systematically compare anti-CD22 based
scFV fused with the two toxins in the prokaryotic (E. coli)
and eukaryotic (Pichia pastoris) expression systems.
Selection of the anti-CD22 single chain variable regions
and characterization of 4KB scFv constructs expressed in
E. coli
A set of primers (forward and reverse, see Additional file 1:
Table S1) was used to amplify the heavy (VH) and light
(VL) variable antibody domains from hybridoma cells on
reverse transcribed anti-CD22 hybridoma mRNA. We ob-
tained the two selected variable domains that were subse-
quently assembled, as described in the Methods section
(see below), inserting a (G4S)3 (one letter amino acid code)
peptide linker joining the two polypeptides. This first
DNA construct was subcloned, sequenced and then ex-
pressed in E. coli BL21(DE3)pLysS cells with a C-terminal
hexahistidine tag to allow easy nickel-affinity purification.
The level of scFv expression in BL21(DE3)pLysS was first
assessed in small-scale cultures. Following IPTG induc-
tion, an overexpressed band with an expected size of
approximately 30 kDa was detected in Coomassie blue-
stained SDS-PAGE gels (Figure 1A, lane 2) which was also
specifically recognized by an anti-histidine antibody in
Western blotting (Figure 1B, lane 2).
The 4KB scFv was next expressed in higher amounts,
being found in inclusion bodies from where it was ex-
tracted after protein denaturation in a urea-containing
buffer followed by purification by nickel-affinity chroma-
tography (see, Methods section). Attempts to refold the
purified proteins did not allow for the full recovery of
the purified denatured molecules, which were largely
lost through precipitation during this procedure, pre-
sumably due to incorrect folding, as the denaturing
agent was gradually removed. Despite these problems,
the final yield was approximately 4 mg of purified 4KB
scFv from a 1 l of E. coli fermentation liquor.
Figure 1 Expression & characterization of the 4KB scFv. Total lysate of non-induced (lane 1) and IPTG-induced (lane 2) E. coli BL21(DE3) pLys
transformed with pET20b(+)4KBscFv were loaded and the expression of the recombinant protein was detected by (A) Coomassie blue staining or
(B) Western blot analysis with anti-His antibody. (C) The binding activity of 4KB scFv (red squares) was compared with that of 4KB128 mAb (blue
diamonds) by flow-cytometric analysis on Daudi cells incubated at 4°C using increasing amounts of purified 4KB128 mAb or 4KB scFv. (D) The
binding of 4KB scFv (50 μg/ml) on Daudi cells is competitively inhibited by increasing concentrations of the parental anti-CD22 mAb pre-incubated
with the cells. The scFv-associated fluorescence without competing mAb pre-incubation is taken as the maximal reference MFI. (E) Internalization
and stability of the anti-CD22 mAb compared to 4KB scFv. Ramos (light blue) and Daudi (green) cells were stained at 4°C with 30 μg/ml 4KB
scFv (continuous line) or 10 μg/ml mAb (dashed line) and subsequently incubated at 37°C for the indicated times, as described in Methods.
Red lines indicate the MFI obtained by staining Daudi cells with the scFv (continuous line) and mAb (dashed line) previously incubated at
37°C for the same time lengths as for the internalization experiment. MFI values are plotted as percentage relative to the fluorescence
obtained for samples kept on ice.
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monoclonal antibody and derived scFv
Before generation of anti-CD22 ITs, the binding proper-
ties of the parental IgG1 mAb and the derived scFv to
the native cellular antigen were confirmed by flow cy-
tometry on CD22+ lymphoid cell lines. As shown in
Figure 1C, a Mean Fluorescence Intensity (MFI) curve
was obtained following staining CD22 expressing cells
with increasing concentrations of mAb (blue line) or
scFv (red line). The expected sigmoid shaped curve was
obtained on Daudi cells (CD22+) but as expected binding
was not seen on two CD22 negative T-lymphoblastoid cell
lines (H9 and HSB-2) as negative controls (data not
shown). On CD22+ Daudi cells the MFI-plateau above 3
nM of mAb, whilst 4KB scFv showed a 10-fold reduced af-
finity to the same cellular target in comparison to the na-
tive bivalent mAb.
The specificity of the molecular target recognized by
the anti-CD22 scFv was also confirmed by analyzing4KB scFv binding on CD22-expressing cells, in a compe-
tition assay with increasing concentrations of the paren-
tal mAb. The scFv-associated fluorescence decreased in
a dose-dependent manner as the amount of anti-CD22
mAb used to pre-stain cells was increased (Figure 1D).
Finally, the avidity of the specific binding of 4KB scFv
to the recombinant extracellular domain of CD22 was
determined using Biacore. The dissociation constant (Kd)
of the interaction between 4KB scFv and recombinant
CD22 target antigen was assessed using Surface Plasmon
Resonance technology. The resulting Kd (koff/kon) evalu-
ated was 5.1 × 10-8 M for the scFv (data not shown), a
value consistent with a Kd of 2.5 × 10
-9 M previously de-
termined for the parental 4KB128 monoclonal antibody
(our unpublished observations), supporting the likely suit-
ability of 4KB scFv for IT constructions.
To ensure that our scFv represented a suitable delivery
vehicle for the design of an immunotoxin, the internal-
ization capability of the antibody fragment was also
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CD22 expressed on the surface of target Daudi and
Ramos cells. By plotting the fluorescence associated with
residual surface-bound scFv against incubation time at
37°C, a rapid fall in extracellular staining was observed,
indicating rapid endocytosis of bound antibody, particu-
larly in Ramos cells (Figure 1E). It is apparent that the
endocytosis trend almost overlaps with the native bi-
valent mAb and univalent 4KB scFv, indicating that the
targeted site(s), rather than the valency of the binding
antibody, is the critical factor in determining the effi-
ciency of uptake. Both antibodies preserved their binding
capability (binding at 4°C) of the two target cell lines
even after a prolonged pre-incubation at 37°C (data not
shown), ruling out the possibility that decrease in MFI
may have been due to intrinsic antibody instability, deg-
radation, dissociation or antigen shedding following in-
cubation at 37°C.
Production and characterization of the 4KB derived fusion
constructs expressed in E. coli
The nucleotide sequence coding for the PE40 truncated
version of Pseudomonas exotoxin A was fused to the 3’-
end of the 4KB scFv, generating a chimeric immuno-
toxin encoded within the pET20b(+) vector (Figure 2B).
The C-terminal hexahistidine tag was exploited for puri-
fication and analytical purposes. The small-scale expres-
sion of the recombinant IT (rIT) in BL21(DE3)pLysS E.
coli yielded an induced protein of approximately 70 kDa,Figure 2 Constructs for the expression of toxin-based fusions in E. co
(D)-derived constructs. Restriction enzyme sites used for the cloning strateg
Sequence of the 218 linker (218 L) in fuchsia color is: GSTSGSGKPGSGEGSTKconsistent with the expected size for a fusion between
the scFv (30 kDa) and PE40 (40 kDa) (Figure 3A and B).
This preliminary induction assay showed that, unlike
the scFv, the derived rIT could be expressed as a single
molecular species, possibly retaining the N-terminal sig-
nal peptide for periplasmic sorting. Although its level of
synthesis seemed to be appropriately lower than that of
the scFv alone, this did not prevent accumulation of the
chimeric protein exclusively in inclusion bodies, as no
detectable rIT could be recovered in soluble form(s) ei-
ther in the cytoplasmic or in the periplasmic compart-
ments (data not shown), indicating a certain propensity
of the fusion toxin to aggregate, presumably due to the
presence of the anti-CD22 recombinant scFv domain.
A larger culture was thereafter grown, induced and
processed to extract the chimeric protein from inclusion
bodies which was then purified and refolded, as described
in Methods. This procedure allowed us to recover ap-
proximately 3 mg/L of rIT from induced bacterial cul-
ture, a yield consistent with those previously reported
for other recombinant ITs that include truncated ver-
sions of PEA [25]. A distinguishing feature of our rIT,
as compared to the scFv polypeptide alone, was a negli-
gible loss of the rIT during the renaturation step. We
calculated that approximately 80% of the denatured re-
combinant protein eluted by IMAC was recoverable after
the refolding procedure.
4KB-PE40 has a good binding capacity as demonstrated
by flow cytometry on Daudi cells (Figure 3C). Furthermore,li. Schematic representation of 4KBscFv (A), PE (B and C) and saporin
y are also shown (for details, see text under Methods section).
G (amino acid one letter code).
Figure 3 Characterization of recombinant ITs expressed in E. coli purified by IMAC. (A) Coomassie staining and (B) Western blot with
anti-His antibody of purified 4KB-PE40 in lane 1, 4KB(218)-PE40 in lane 2 and 4KB(218)-SAP in lane 3. (C) Comparison of the binding characteristics
of 4KB-PE40 (blue diamonds), 4KB(218)-PE40 (green circles) and 4KB(218)-SAP (red triangles) analyzed by flow-cytometry using Daudi cells incubated at
4°C with increasing concentrations of each IT.
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we performed protein synthesis dose–response assays
which demonstrated a cytotoxic activity of 4KB-PE40
on Daudi cells with an IC50 of approximately 0.3 nM
(Figure 4). The cytotoxicity observed was dependent on
the presence of the anti-CD22 scFv domain fused to
PE40 since the toxin alone or the scFv alone were sub-
stantially less effective against Daudi cells, while in turn
the cytotoxicity of the rIT towards CD22 negative cell
lines was, as expected, significantly less (Table 1). Add-
itional evidence of the immunospecificity of our rIT for
CD22 as the target antigen is further supported by the
observation that co-incubation with an excess of wholeFigure 4 Characterization of 4KB-PE40 IT immunospecificity for
CD22 expressed on Daudi cells. The cytotoxic assay was performed
incubating Daudi cells for 72 hours with increasing concentrations
of 4KB-PE40 in the presence (pink squares) or absence (blue
diamonds) of a fixed concentration of the corresponding parental
4KB128 monoclonal antibody. Inhibition of protein synthesis is
expressed as percentage of [14C]-leucine incorporation compared to
the control samples (untreated cells).monoclonal parental antibody abolished the cytotoxicity
of rIT, indicating displacement of the rIT by the com-
peting whole antibody (Figure 4).
The sequence coding for PE40 was also sub-cloned at
the C-terminus of a different 4KB scFv format in which
the VH and the VL domains were joined through the 218
linker (Figure 2C), a more flexible and hydrophilic se-
quence [26].
The purified 4KB(218)-PE40 fusion protein showed
chemical and physical properties similar to that of 4KB-
PE40. The recombinant IT had a molecular mass of ap-
proximately 70 kDa and was recognized by the anti-His
antibody in Western blotting (Figure 3A-B, lane 2).
Additionally, the levels of synthesis and the final yields
of the latter fusion protein were also comparable to
those of the first rIT made with the (G4S)3 linker.
In parallel experiments, we utilized the latter anti-
CD22 scFv to deliver the 30 kDa plant-derived toxin RIP
saporin. Since a more flexible and hydrophilic linker
may be advantageous for the construction of a rITs, we
decided to link the sequence coding for a plant saporin
isoform [27] to the 4KB(218) scFv version and the latter
rIT was also expressed in bacteria and purified, asTable 1 Comparison of concentrations of the 4KB-PE40 IT,
PE or the scFv alone inhibiting protein synthesis by 50% of
control values (IC50)
Daudi Ramos HSB-2 H9
IC50
IT 7 nM 4 nM >300 nM >300 nM
PE 200-300 nM >750 nM 60 nM >750 nM
scFV >3200 nM >3200 nM >3200 nM >3200 nM
CD22+ cell lines Daudi and Ramos or CD22− lines HSB-2 and H9 were exposed
for 48 h to the 4KB scFv-derived immunotoxin (IT) or to native PE exotoxin A
(PE) or 4KB antibody fragment alone (scFv) and cytotoxicity was evaluated by
protein synthesis inhibition assay as described in the Methods section.
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Methods). However, in the case of rIT containing a sa-
porin domain we observed a lower level of rIT synthesis
than that observed for PE40 containing rIT in E. coli fol-
lowing IPTG induction. This phenomenon was apparently
not dependent on possible host auto-intoxication effects
observed during saporin expression in several hosts [28],
since the E. coli growth curve of the bacterial transformant
strain was not influenced by the expression of the fusion
protein (data not shown).
Nevertheless, around 4 mg/L of this saporin fusion
protein could be extracted from inclusion bodies but
more than 90% was lost during the renaturation process
due to aggregation and concomitant precipitation caused
by what we presume must be due to the instability of
this particular IT construct. Indeed it has been shown
previously that saporin and fusion proteins incorporating
this RIP have a low propensity to refold after urea denatur-
ation procedures (D. Lappi, personal communication).
The binding characteristics of the different recombinant
ITs produced by the bacterial expression system were
compared by flow cytometry as described in Methods. As
shown in Figure 3C the data demonstrate overlapping
binding curves on Daudi cells.
Next, rITs produced in bacteria were tested in a pro-
tein synthesis inhibition assay on Daudi cells (Figure 5).
4KB-PE40 (green) and 4KB(218)-PE40 (blue) showed
very similar cytotoxic activities with an IC50 of approxi-
mately 0.1 nM, while unexpectedly, the 4KB(218)-SAP
produced in E. coli (violet) failed to show any cytototoxi-
city, we presume due to IT instability problems, as al-
luded to above. We did not assay the 4KB(G4S)3-SAPFigure 5 Cytotoxicity of 4KB128-derived rITs for CD22+ Daudi
cells. Protein synthesis inhibition assay on Daudi cells exposed for
72 hours to increasing concentrations of 4KB-PE40 (blue diamonds),
4KB(218)-PE40 (green circles) or 4KB(218)-SAP (violet triangles).
Protein synthesis inhibition is expressed as a percentage of [14C]-leucine
incorporation compared to untreated control cells. Error bars represent
standard deviations from the mean of triplicate samples.construct, since parallel experiments performed in P. pas-
toris demonstrated that this construct was incapable of
giving rise to inducible clones in the P. pastoris expression
system (see Figure 6).
Overall, these data confirm that rITs formed by PE40
fused to the anti-CD22 scFv joined by different linker
peptides can be successfully produced and purified in E.
coli and, most importantly, are biologically active. In
contrast, a similar construct based on a saporin toxin
domain was not properly expressed in bacteria and the
renatured purified rIT molecules therefore failed to in-
toxicate CD22+ target cells.
Selection of the 4KB derived, best-suited fusion constructs
expressed in P. pastoris
Saporin and a number of recombinant fusion proteins
have been previously expressed with some success in E.
coli [4]. However, eukaryotic hosts would seem much
more suitable for expression of saporin chimaeras [29],
as we recently demonstrated by exploiting the microbial
eukaryotic host Pichia pastoris as an expression platform
[30]. Having observed the production of aggregation-
prone product(s) during expression of our anti-CD22
PE40 IT in E. coli, and having obtained low, non- func-
tional amounts of this saporin-based IT in bacteria, we
decided to compare the expression of companion saporin-
based ITs in P. pastoris.
With this aim, we prepared a panel of constructs (see,
Figure 6A) fusing the sequences coding for the anti-
CD22 VH and VL domains alternatively connected by
using (G4S)3 or 218 linkers, as described for 4KB-PE40,
to a saporin yeast-optimized sequence [30] either carry-
ing an N- or C-terminal hexahistidine tag.
The first attempts to replate zeocine-resistant trans-
formed clones and induce fusion protein expression
were unsuccessful as we obtained only a very low num-
ber of transformants, in some instances as few as only
one or two transformant zeocine-resistant clones, which
were incapable of expression induction (Figure 6A, for
examples see schemes for constructs 2a and 3).
As a control, Pichia cells transformed with an enzy-
matically inactive saporin mutant construct termed
4KB-SAPKQ (named KQ because a Lysine K and a Glu-
tamine Q residue were introduced at the saporin cata-
lytic site) yielded plates with the expected number of
several hundred viable growing colonies (Figure 6A, see
scheme for construct 2b) all of which were zeocine-
resistant and all of which could be induced to express,
on a small-scale, up to 2 mg/L of the fusion protein con-
taining inactive mutant KQ saporin. This observation
suggests that one likely reason for the unsuccessful ex-
pressions of IT was the high toxicity of the enzymatically
fully active saporin domain towards host Pichia cells.
Similar effects have also been previously reported during
Figure 6 4KB-SAP and 4KB-PE40 fusions expressed in Pichia pastoris G115 (his4). (A) Schematic representation of saporin- (C1-9) or
PE-based (10) -4KB128-derived fusion constructs. C1: Pichia-fully optimized Construct 1 expressing clone. (B) Western blot analysis of 4KBopt218L-SAP
clones. Secretion yields were estimated at 1-2 mg/L and compared to induced mock or positive control anti-PA63scFv-SAP expresser clones.
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taining saporin fused with the Amino-Terminal Frag-
ment of human urokinase (ATF-saporin) in different
host cells, including P. pastoris [28].Expression of the 4KB scFv construct alone yielded the
expected number of secreting clones, and these clones
were further analyzed following a medium scale induc-
tion (see Additional file 2: Figure S1) which all gave a
Della Cristina et al. Microbial Cell Factories  (2015) 14:19 Page 9 of 17good secretory yield, further supporting the notion that
the low number of transformants we obtained for rIT
constructs was in all likelihood due to intoxication of
the host by fully active saporin.
Codon-optimization has already been shown to mark-
edly decrease the toxicity issues associated with saporin
expression in P. pastoris and also found to be essential
for obtaining clones that expressed high levels of active
saporin [30]. For these reasons, we decided to design a
yeast codon-optimised anti-CD22 sequence for fusion to
the N-terminus of mature saporin through a trialanine
linker, which has previously been successfully used for
recombinant ATF-saporin constructs [29] (Figure 6A).
A synthetic optimized gene was therefore assembled as
described in the Methods section in which a yeast codon-
optimized sequence coding for saporin [30] fused with dif-
ferent versions of the scFv with either a (G4S)3 linker, not
sequence optimized (colour coded turquoise in Figure 6A)
or the 218 linker (colour coded purple) joining the VH and
VL codon-optimized variable chains (colour coded yellow
in Figure 6A) for expression in P. pastoris. Among all the
constructs obtained, constructs termed C1 and C4 were
then analyzed further as described below.
Codon-optimization of the scFv domain appears to be
important to enable an increase in the potential number of
secreting clones that are capable of achieving a minimum
of 1–2 mg/L of fusion protein production. In the supple-
mentary figures we show some additional data for con-
structs 6 and 9 that gave rise to expresser clones in
medium scale inductions that reached values as high as 5–
10 mg/L. However, neither of these had any demonstrable
saporin catalytic activity even when they were selected
among a much larger number of transformants, directly
on plates (see Additional files 3, 4, 5 and 6: Figures S2-S5).
Indeed, Construct 9 which has the saporin C-terminus
blocked by a G4S linker peptide that joins the toxin to the
scFv domain, showed the largest number of transformant
(360 clones) but no enzymatic activity was detectable when
the purified fusion protein was assayed (data not shown).
Appending extensions at the C-terminus has previ-
ously been reported to cause inactivation of saporin
(Sap-VSAV, single letter aminoacid code) assayed by an
in vitro cell-free inhibition assay, but enzymatic activity
was “activated” once this molecule was used against
whole viable cells [21] suggesting that a proteolytic acti-
vation step takes place either extra- or intracellularly.
Finally, constructs 5 and 6 expressed with an hexahisti-
dine tag appended at the N-terminus of the scFv were not
recognized by an anti-his polyclonal antibody (Additional
file 6: Figure S5), suggesting that proteolytic removal of
this tag may have taken place, as shown for the PEA
fusion as described below.
Since it is known that a gelonin-based IT (having a VL
domain connected to the VH antibody domain via the 18-amino acid 218-flexible linker GSTSGSGKPGSGEGSTKG,
amino acid one letter code) shows enhanced resistance to
proteolysis and reduced aggregation properties of scFvs
when expressed in bacterial systems [26,19], we decided to
make two constructs (constructs 7 and 8 in Figure 6A)
that were designed with a reversed VL-VH configuration,
in contrast to all the other constructs.
Among alternate construct configurations that we also
explored, the hexahistidine tag appended at N-terminus
in the IT (Figure 6A, contructs 5 and 6) or the saporin
domain cloned at N-terminus of the scFv (Figure 6A,
construct 9) gave rise to fusion polypeptide produced in
medium scale with considerable yields (see Additional
files 3, 4 and 5: Figures S2-S4), but when they were puri-
fied and tested on Daudi cells, no cytotoxic activity was
detected (data not shown). Finally, when VH-VL orienta-
tion constructs were prepared (Figure 6A, constructs 7
and 8) in the hope of increasing the scFv stability/flexi-
bility or its affinity towards the target antigen, as pre-
viously demonstrated by others [31], no expression was
obtained. (see Additional files 3, 4 and 5: Figures S2-S4).
Overall, we may draw the following conclusions from
the data we obtained with the VH-VL configurations
examined so far. Our results indicate that 4KB scFv
behaves as a poor secretory domain, prone to aggrega-
tion (found in inclusion bodies in bacteria) and under-
goes misfolding which may explain why transformation
of fusion constructs containing an active saporin domain
resulted in a very few transformants: if the misfolded
polypetides were retro-translocated to the cytosol for
degradation by the ER-associated degradation pathways,
saporin would escape segregation in the endoplasmic
reticulum being active against cytosolic ribosomes. Con-
sistently, secretion levels of the KQ control fusion pro-
tein (contruct 2b, Figure 6) were also extremely low, at
least 10 times lower than when saporin KQ is expressed
alone in GS115(his4) [30]. This would suggest that when
this scFv domain is fused even to a good secretory
protein it has direct detrimental effects on the overall
expression/secretion levels.
An example of saporin-based CD22 immunotoxin
expressed in Pichia pastoris
Notwithstanding the major problems of expression,
among the Pichia zeocine–resistant transformants ob-
tained, twenty independent clones were available for
screening for inducible expression. The best expressing
clones were selected following screening in 5–10 mL, in
small-scale inductions [30]. Expression yields for the ITs
ranged between 1 and 2 mg/L (Figure 6B). We next
undertook medium-scale preparations starting at a turbid-
ity of 10 OD/mL which were prepared and induced for
48 h as described previously (see S1 as a representative
example and [30]). Collected media were concentrated
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tography to purify His-tagged fusion proteins or as an al-
ternative cation exchange chromatography that exploits
saporin’s extremely high PI [4,28,2].
We decided to explore the construct C1 as a prototype
for Pichia pastoris expression. The untagged C1 con-
struct, however, was difficult to purify, we believe be-
cause its isoelectric point was not sufficiently high
enough for cation-exchange purification procedure to
give the resolution and efficiency needed (data not shown).
C1 activity was first assayed on Daudi cells and displayed
marked cytotoxicity after 20 hours exposure. C1 cytotox-
icity was compared to that of unconjugated seed-extracted
saporin (Figure 7A) in a protein synthesis inhibition assay.
The recombinant saporin-based scFv fusion showed an
IC50 of 7 nM, being approximately two orders of magni-
tude higher than free saporin (Figure 7B) but lower than
the conventional (chemical cross-linked) IgG (anti-CD22,
4KB128-SAPORIN) conjugate, reported to be in the order
of tens of picomolar [6]. In order to confirm that the C1
activity was mediated via the CD22 target molecule, a com-
petitive inhibition assay was performed by co-incubating
Daudi cells for 72 hours with a fixed amount of C1 scFv
saporin fusion protein together with increasing concentra-
tions of 4KB128 monoclonal antibody (Figure 7B). An
excess of free 4KB128 native antibody competed with the
IT for the target antigen and completely abolished C1
cytotoxicity.
As C1 was active and expressed in sufficient amounts,
a similar construct termed Construct 4 (C4) was pre-
pared in which a hexahistidine tag was appended to the
C-terminus of saporin (Figure 6A, compare C1 and C4)
to allow for IMAC affinity purification of the IT.Figure 7 Cytotoxicity of 4KB128-SAP (C1) produced in P. pastoris for
increasing concentrations of 4KBscFv-SAP (red triangles), seed SAP (light blue
synthesis is expressed as percentage of [3H]-leucine incorporation compared t
the mean of triplicate samples. (B) A competitive inhibition assay was perform
10−8 M in the presence of increasing concentrations of 4KB128 parental mono
of 4KB128 MAb). Inhibition of protein synthesis is expressed as percentage of
represent standard deviations from the means of triplicate samples. 4KB128 anC4 purification steps are shown in Figure 8. Unbound
material contained a wide range of endogenous proteins,
as can be seen in lane 2, but contained virtually no
saporin immunoreactivity (data not shown). Elution with
100 mM imidazole was sufficient to detach the majority
of the bound C4 scFv-saporin fusion protein with a
minor amount eluting at 300 mM imidazole, as evalu-
ated both by the intensity of the single eluted bands in
lanes 3 and 5 in the silver-stained gel. This affinity puri-
fication procedure allowed for recovery of 30-40% of the
induced fusion protein, significantly better than recover-
ies obtained for the C1 construct purified by ion ex-
change chromatography.
Subsequently, the activity of purified C4 construct was
assessed on Daudi cells, and was found to be active in
the nanomolar range (Figure 9), similar to the cytotox-
icity observed for 4KB-PE40 produced in E. coli, This in-
dicates that the codon optimization of the scFv and the
insertion of the 218 L linker were critical to allow for
proper folding, expression and activity of the IT in
Pichia cells while the His tag did not interfere with its
activity contrary to the observations we made with con-
struct 9. The protein synthesis inhibitory activity of the re-
combinant PE-based scFv fusion was observed to have an
IC50 of 0.36 nM slightly lower than the 1 nM observed for
the C4 anti-CD22 scFv fusion to saporin. We also com-
pared the activity of the above mentioned ITs to that of
unconjugated seed-extracted saporin or to recombinant
saporin expressed in P. pastoris. Notably the latter two
displayed identical activity in Daudi cells with an IC50 of
approximately 0.6 μM. Thus, 4KB218Lopt-SAPHis (C4) is
the scFv anti-CD22 fusion to saporin that in our hands
performs the best with respect to expression levels andCD22+ Daudi cells. Daudi cells were exposed for 72 hours to
squares) or mock supernatant (violet circles) (A). Inhibition of protein
o untreated control cells. Error bars represent standard deviations from
ed by incubating Daudi cells for 72 hours with of 4KB128scFv-SAP at
clonal antibody (filled and open red circles refer to two different batches
[3H]-leucine incorporation compared to untreated control cells. Error bars
tibody used alone over the full concentration range was not cytotoxic.
Figure 8 Characterization of 4KB128-SAP (C4) produced in
P. pastoris and purified by IMAC. Silver staining of purified
4KB128-SAP (C4). MW markers are shown in the far right lane.
Figure 9 Protein synthesis inhibition in Daudi cells exposed for
72 hours to increasing concentrations of 4KB-PE40 produced in
E. coli (green circles), C4 (4KBopt218L-SAPHis6) (red triangles),
rSAP (open blue squares), seed SAP (solid blue squares).
Inhibition of protein synthesis is expressed as percentage of
[3H]-leucine incorporation compared to untreated control cells. Error
bars represent standard deviations from mean of triplicate samples.
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activity to construct 1. The activity of the histidine-tagged
C4 construct was directly comparable to the untagged C1
construct containing the 218 linker.
Is bacterial PE efficiently expressed as a fusion with
4KBscFv in Pichia pastoris?
Finally, since fusions between antibodies and bacterial
toxins have been successfully expressed in P. pastoris, as
demonstrated by Neville and coworkers for diphtheria
toxin [24], we explored the feasibility of expressing PE40
chimeras using this host, in which antibody or other
secretory targeting domains might undergo better fold-
ing and quality control in the oxidizing environment of
the ER lumen. We transformed the eukaryotic host
Pichia pastoris with the fusion construct 4KB218Lopt-
PE40 (Figure 6A) containing the yeast codon-optimized
sequences for both the anti-CD22 scFv and the toxin do-
mains. An initial screening of the transformed colonies
by Western blot analysis (shown in Figure 10) revealed
that no intact polypeptide was secreted into the P. pas-
toris medium and indeed, no band was detectable at the
expected molecular mass (70 kDa). A pattern of threeFigure 10 Expression of 4KB218Lopt-PE40 in P. pastoris. A
sample from a 72-hour medium scale induction of a GS115 clone
expressing 4KB218Lopt-PE40 was analyzed by Western blotting with
anti-PE serum. Concentrated medium of the induced culture was
loaded in lane 1; 20 ng of recombinant PE40 expressed in E. coli
were loaded as a control in lane 2.
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radation products with molecular masses of 29, 37 and
42 kDa, respectively were detected. An in silico study of
the aminoacid sequence of the IT anticipated expressed
rIT molecule showed that it contained potential cleavage
sites recognized by furin-like enzymes (RXXR) which
would be expected to release protein fragments of sizes
comparable to those visualized by the Western-blotting.
We therefore speculate that proteases present in the
yeast medium were responsible for degrading the se-
creted recombinant 4KB218Lopt-PE40 fusion protein. In
this respect several proteases have been described fol-
lowing secretome analysis of P. pastoris after methanol
induction [32]. To confirm whether this hypothesis is
correct, we conducted a study to test if native PE was
cleaved by culture medium obtained from P. pastoris ex-
pressing the recombinant IT following induction by
methanol. Native PE was incubated 1 h with: 1) PBS
alone as a control, 2) Pichia induction 48 h medium, 3)
GS115-mock transformed induction medium after a
48 h induction (pPiczαA empty vector) or 4) induction
medium containing 1 mM of the serine protease inhibitor
PMSF after a 48 h induction. As shown in Figure 11A, na-
tive PE incubated with non-inoculated medium remained
intact, showing the expected size of PE in the control lane.
We can therefore exclude the possibility that proteolytic
activity intrinsic to the culture medium was responsible
for cleaving the 4KB218Lopt-PE40 recombinant protein.
However, when samples of PE were incubated with
medium after methanol induction of P. pastoris transfec-
tants, four degradation products were observed; these
were less intense in the presence of proteases inhibitors.
This finding strongly implies that P. pastoris secretes pro-
teases into the culture medium that proteolytically cleaves
native PE and that the amount of degradation observed
was decreased by the addition of protease inhibitors. An
in silico study of the native PE sequence revealed five pu-
tative cleavage sites (Figure 11B): the predicted C-terminal
PE fragments have molecular masses similar to thoseFigure 11 Cleavage pattern assessment of secreted PE. (A) Western bl
different conditions. CTR (control): native PE incubated with PBS; αA BMMY
mock transformant pPICZαA (αA) clone; αA BMMY PMSF: as αA BMMY but
only. (B) In silico study of identifiable furin-like cleavage sites in the native Pshown by Western-blot analysis. By the mutagenesis of
Arg243 in the furin cleavage consensus site we could re-
lease the 37 kDa peptide fragment. This mutagenesis was
performed in the nucleotidic sequence of IL4-PE40, a re-
combinant immunotoxin available in our laboratory that
contains the same codon optimized sequence of PE40 but
a different binding domain. The R243A mutation which
abolished the furin cleavage site also prevented the deg-
radation of PE C-terminal fragment which could no longer
be detected by Western blotting with anti-PE serum (data
not shown). Additional studies will be needed to confirm
whether after mutagenesis of the potential cleavage sites, a
PE-based IT could be expressed that retains intact catalytic
activity in vivo.
Conclusions
In the present work we compared a prokaryotic and a
eukaryotic expression system used for the production of
recombinant immunotoxin molecules based on PE or
saporin toxin domains (a flow chart comparing the two
expression systems is reported in Additional file 7:
Figure S6). Immunotoxins are promising therapeutics
for the targeted therapy of leukemia, lymphoma and
other malignancies. Targeting CD22 expressed on B-cell
tumours with the 4KBscFv fused to either Pseudomonas
exotoxin A or to the plant toxin saporin would theoret-
ically allow for multiple administrations by switching to
a different IT carrying the alternative toxin domain but
with the same targeting domain This would be a particu-
larly attractive strategy if a patient develops an antibody
response against one of the toxin domain(s) during
treatment.
Overall our data demonstrate that we may use a com-
mon targeting moiety to deliver toxins of plant or bac-
terial origin and that the resulting fusion molecules
show similar potencies in terms of their protein inhib-
ition capabilities. However, the molecules containing the
bacterial toxin are better expressed in the E. coli system,
whilst the yeast P. pastoris is confirmed to be a betterot analysis of native PE fragments derived from PE cleaved under
: native PE incubated with BMMY after 48 h of induction of the GS115
PE was incubated in addition + 1 mM PMSF BMMY: induction medium
E sequence.
Della Cristina et al. Microbial Cell Factories  (2015) 14:19 Page 13 of 17host for saporin-based chimaeras in terms of recovery of
active products once codon-usage optimization of both
the toxin and the targeting scFv domains has been
undertaken.
Saporin is a eukaryotic secretory protein and despite
its lack of disulphide bonds or N-glycosylation sites, it is
a polypeptide that would appear to be better expressed
in the environment provided by the endoplasmic
reticulum. When saporin is fused to a “non conven-
tional” unfavorable domain, as with the “synthetic” scFv,
misfolding may occur and result in greater host toxicity
issues, thus reducing expression levels. The reason why
codon-usage optimization at least in part, counteracts
such an effect by the scFv domain expressed in Pichia
requires further investigation. The advantage of both the
microbial expression platforms used here is that they
can both be easily scaled up for industrial production for
such therapeutic proteins. Finally, we were able to deter-
mine that P. pastoris is not a suitable host for the ex-
pression of PE-derived fusion proteins because of the
potential cleavage sites present in native PE that are rec-
ognized by furin-like enzymes secreted by P. pastoris
into the culture medium.
Methods
Materials
All the Materials were of analytical grade.
Recombinant CD22 was purchased from SBH SCIENCES.
4KB128 hybridoma cells were kindly provided by Profes-
sor Karen Pulford, University of Oxford and anti-saporin
rabbit antiserum was provided by one of our laboratories
(DJF/SUF).
The synthetic genes coding for optimized scFv or opti-
mized PE-40 sequence were assembled by Genscript
(Piscataway, NJ, USA), based on the available P. pastoris
coding sequences (CDS) in Biomed Central (64,359 co-
dons with corresponding triplet frequencies, choosing
those most frequently represented in highly expressed P.
pastoris proteins for the construction of the synthetic
genes that were subcloned in pUC57 recipient vector, as
for the codon-optimized saporin sequence [30] obtaining
the pUC57-PE40opt construct and 4KB218scFvopt.
The pPICZalpha series of vectors from Invitrogen
were used for subcloning the DNA constructs to obtain
recipient vectors for expression in GS115 (his4) Pichia
pastoris strain.
Plasmid construction for the expressions in E. coli
The 4KB128 hybridoma secreting murine IgG directed
against human CD22 were cultured under the same con-
ditions used for other cell lines (see below).
Total RNA was extracted using the SV Total RNA Isola-
tion System (Promega, Madison, WI, USA) according to
the manufacturer’s instructions. Reverse transcription wasperformed using M-MLV retrotranscriptase from Invitro-
gen and a mix of random primers (Invitrogen) to obtain
cDNA according to the manufacturer’s instructions.
The sequences coding for the variable domains of
heavy (VH) and light (VL) immunoglobulin chains were
amplified by PCR reactions on 1 μg cDNA using a panel
of 25 forward and 4 reverse oligonucleotides for each
variable domain (25 VH forward primers and 4 JH re-
verse primers; 25 VL forward primers and 4 JL reverse
primers, (see Additional file 1: Table S1). Forward
primers were designed based on highly conserved se-
quences at the 5’-end of DNA fragments for VH and VL
domains from several families of murine immunoglobu-
lins; reverse primers were instead inferred from the J re-
gions located at the 3’-end of VH and VL DNA regions.
Each forward primer was tested in a PCR reaction that
included a mix of the four reverse primers. Once the
best forward primer had been thus selected, it was used
in four individual PCR reactions, each with a single re-
verse primer.
The PCR products generated by each of the putative
primer pairs were sequenced and compared with se-
quences present in the Genbank database of variable do-
mains deriving from murine immunoglobulins.
The primer pairs that allowed for a correct amplifica-
tion of VH and VL genes were then re-designed as modi-
fied versions by inserting the suitable restriction sites for
the cloning into the recipient vector: NcoI and XhoI
were inserted into the primer for the amplification of
the VH chain and PstI and NotI for the VL chain.
The VH and VL chains were therefore further amplified
using the latter pairs of primers, i.e. 4HF, 4HR in the
case of amplification of the VH domain and 4KF, 4KR in
the case of the VL (Additional file 1: Table S1). The
resulting PCR fragments were inserted into a pHEN1
vector derived from a clone obtained from the ETH-2-
Gold library and containing a (Gly4Ser)3 linker between
the two previously encoded VH and VL regions. The final
construct, named 4KBscFv, was amplified with primers
4HF and 4KR (Additional file 1: Table S1) then sub-
cloned into the pET20b(+) expression vector which pro-
vided a carboxy-terminal hexahistidine tag for nickel
affinity protein purification, in this way we obtained a
first construct which we named pET20b(+)4KBscFv(XP).
Two point mutations were then inserted into the plas-
mid pET20b(+)4KBscFv(XP) using the QuickChange
Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA,
USA) in order to remove the restriction sites for PstI
and XhoI by respectively using the primer pairs PSTmut1/
PSTmut2 and XHOmut1/XHOmut2 (Additional file 1:
Table S1). The resulting vector was called pET20b(+)4KB
(G4S) scFv (Figure 2A).
The sequence of PE40 was amplified from the expres-
sion plasmid pHL310 (kindly provided by Prof. Haya
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for Medical Research - Israel-Canada, Department of
Biochemistry and Molecular Biology, Faculty of Medicine,
Jerusalem 91120, Israel) which encodes the IL-2-PE40 fu-
sion protein using PEF and PER primers (Additional file 1:
Table S1). The NotI cut PCR fragment was inserted at the
C-terminus of the 4KBscFv sequence into the pET20b(+)
vector cut with the same enzyme to obtain the construct
of the immunotoxin 4KB-PE40 (Figure 2B).
To replace the classic (G4S)3 linker with the longer
and more hydrophilic 218 linker, and obtain the 4KB
(218)scFv construct in which the heavy and light chains
of the variable domains are joined through the 218
linker, two 218 F and 218R oligonucleotides were syn-
thesized (Additional file 1: Table S1). Briefly, the oligo-
nucleotides were mixed with a reaction buffer (100 mM
TrisHCl pH 7.5, 200 mM NaCl, 60 mM MgCl2), incu-
bated for 2 minutes at 80°C to enable primer annealing
and then cooled to room temperature. The primer ex-
tension was performed using Klenow fragment (Fermen-
tas) according to the manufacturer’s protocol. The
double-stranded fragment was digested with PstI/XhoI
and cloned into the pET20b(+)4KBscFv vector to obtain
the final construct pET20b(+)4KB(218)scFv.
The sequence of PE40, amplified as described above,
was inserted into pET20b(+)4KB(218)scFv at the C-
terminus of the scFv sequence to obtain the immunotoxin
construct 4KB(218)-PE40his (Figure 2C).
The same cloning strategy was used for construction
of the pET20b(+)4KB(218)-SAPhis vector (Figure 2D)
amplifying the saporin native sequence from a saporin
expression plasmid, as previously described [30] by using
the primers SAPF and SAPR (Additional file 1: Table S1).
DH5α-competent bacteria were used for DNA trans-
formation and large-scale preparation, and the putative
positive clones were confirmed by sequencing using T7
promoter and T7 terminator primers for pET20b(+) de-
rived constructs. All our DNA sequence analyses were
performed by BMR Genomics (Padua, Italy) and primers
for DNA amplifications were synthesized by Eurofins
MWG Operon.
The E. coli strain BL21(DE3)pLysS was transformed
with 50 ng of the plasmids described above and grown
at 37°C in Luria-Bertani broth containing 100 μg/mL
ampicillin. To induce protein expression, 1 mM isopropyl-
1-thio-ß-D-galactopyranoside (IPTG) was added to the
culture and the induction was carried out for 3 hours at
30°C after which the cell culture was harvested by centri-
fugation (10000 x g, 10 min).
Protein purification from bacterial cultures
The bacterial cell pellet was resuspended in 100 ml resus-
pension buffer (50 mM Na2HPO4, 0,5 M NaCl pH 7.5).
25 μg/mL DNase, 0,1 mg/mL lysozyme, 1% Triton X-100,1 mM PMSF, 10 mM MgCl2 were added and the solution
was sonicated and then centrifuged at 13000 x g for
20 min at 4°C. The precipitated insoluble intracellular
fraction was separated and the pellet was dissolved by son-
ication followed by 2 hours incubation at room
temperature in 50 mL of solubilization buffer (8 M urea,
50 mM Na2HPO4, 0.5 M NaCl pH 7.5).
Solubilized proteins were purified through a 2 mL Ni-
Sepharose Fast-Flow resin (GE Healthcare) followed by
elution of bound protein with the same solubilization
buffer containing 500 mM imidazole.
Refolding of urea-denatured proteins from inclusion
bodies was attained by multi-step dialysis in refolding
buffer (50 mM TrisHCl, 0.5 M NaCl, 0.4 M L-Arg,
pH 7.5) that gradually decreased the concentration of
denaturant. The final dialysis step was carried out in
PBS (pH 7.2) for 12 hours.
Rationale for the Pichia expression constructs, selection of
pichia gs115(his4) trasformants
A SfiI-NotI fragment of a pHEN1 construct containing
the 4KB antibody single-chain variable fragment (scFv)
was purified and inserted into the SfiI-NotI-cut pPICZal-
phaB recipient vector while a second construct in which
the amino acid sequence of this first scFv version was
fused to the N-terminus of a saporin yeast codon opti-
mized sequence [30] via an alanine tripeptide linker
(encoded within the NotI sequence) was also obtained
and clone integrity confirmed by DNA sequencing by
BMR Genomics (Padua, Italy), that custom performed
all the DNA sequence analyses of constructs described
herein. A codon-optimized DNA sequence encoding the
anti-CD22 scFv was custom synthesized by Genscript
company as described previously for the saporin se-
quence optimization [30] was also used to obtain some
of the fusion constructs, following the same cloning
strategy.
Electrocompetent GS115 (his4) P. pastoris cells were
prepared according to protocols from Invitrogen. A best
expresser strain GS115 (his4) able to support PA63-
saporin expression was used as control in some induc-
tions. A Bio-Rad Gene pulser apparatus (Bio-Rad, Milan,
Italy) was used for electroporation of linearized DNA
constructs for genomic integration. DNAs were carefully
quantitated in ethidium-bromide-stained agarose gels,
and equivalent amounts of DNA (5–10 μg) resuspended
in sterile water were used for each electroporation cu-
vette. Linearized empty pPICZalpha vectors were always
used as control for the mock-transformant cells. Then,
either 200 or 600 μl of transformed cells were plated for
selection on YPD [1% (w/v) yeast extract, 2% (w/v) pep-
tone or tryptone, and 2% (w/v) dextrose] plates contain-
ing 18.2% sorbitol (YPDS) in the presence of 1.5% (w/v)
agar and 50 μg/mL Zeocin (Invitrogen). Colonies started
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domly selected colonies were restreaked onto YPDS-
zeocin plates. In the case of non optimised scFv fusion
constructs only few colonies could be selected and al-
most no induction or very little expression of the fusion
construct could be observed in one or two clones.
At least 10 different fusion constructs have been de-
signed, produced and separately introduced into Pichia
GS115(his 4) cells, using as a starting point the yeast
codon optimised saporin (SAPopt) sequence which has
been fused to alternate versions of the anti-CD22 single
chain variable fragments that were collectively termed
4KB. For further details please refer to Figure 6A in
which clone identifying numbers refer to the (best) refer-
ence clone(s) obtained and further analyzed for each
transformation set. AAA in aminoacid one letter code
refers to the encoded Alanine linker joining the two
variable single chain domains to the toxin domain. Basic
fusion construct configuration generally included the
Preproalpha factor domain which was always used as a
common yeast secretory domain, in all our constructs
(not shown in Figure 6) optimized saporin followed by
AAA linker, except for constructs labeled 7, 8 that
started with the heavy chain variable (VH) antibody do-
main immediately following the Preproalpha factor do-
main and construct 9 which has saporin domain
connected via a G4S linker to the scFv optimized 4KB
domain.
We also introduced and investigated the effects of a
change in linker sequence between VH and VL, leading
to what we term “218 L derived constructs”. Two alter-
nate construction options were explored, by inserting
instead of the classic (G4S)3 linker between the VH and
VL antibody domains, a longer and more hydrophilic
218 linker. We also checked for the expression of fusions
with an hexahistidine tag placed either at the C-
terminus of the fusion toxin or at its N-terminus, in the
latter case the 6xHistag was placed just beyond an endo-
protease Kex-2 like site that should be recognised allow-
ing for removal of the transient alpha factor secretory
domain within the Golgi complex. Overall, only two
construct(s) gave us a successful clones, construct 1 and
construct 4 that are quite similar, because they both
contain the 218 linker between VH and VL of the codon
yeast optimized 4KBopt sequence, differing only for the
presence of an histidine tag at the saporin C terminus in
clone 4.
After obtaining the pUC57-PE40opt construct from
Genscript, the PE40 optimized sequence, including the
C-terminal hexahistidine tag, was amplified by PCR on
pUC57-PE40opt with optPE40 and optPE6his primers
(Additional file 1: Table S1) and ligated in the NotI-
XbaI-cut pPicZalphaB-4KBopt218L; the final construct
was named 4KBopt(218)-PE40his (Figure 6A).Pichia expression screening procedures and large scale
induction conditions
Screening conditions were either small-scale inductions
of Pichia independent clones after being restreaked onto
YPDS-zeocin plates. Single colonies were picked into 5–
10 mL broth and at 2OD/mL these were either non-
induced or induced for 48 h with 0.5% Methanol in
BMMY. Equivalent samples of non-induced (NI) or
methanol-induced (I) media were loaded, subjected to a
SDS-PAGE and Western-blot analysis using anti-saporin
serum, as shown in Figure 6B.
As negative control, an induced mock-transformant
clone was also loaded in same amounts, to confirm no
reactivity was present, whereas as a positive control of a
small-scale induction of the model IT antiPA63-SAP [30]
was also loaded, to confirm the expected size and to
roughly compare expression levels of the fusion polypep-
tides under small-scale induction conditions, which were
also compared to standard seed saporin for protein
quantitation’s.
Among the 20 clones picked and induced, we then se-
lected a “best expresser” clone showing almost no im-
munoreactivity in the NI-condition but when induced
showing an immune-reactive band of the expected size
for a saporin-scFv fusion (around 55 KDa) co-migrating
with the model control scFv fusion. In some experiments
we noticed the presence of faint reactive bands migrat-
ing at the size of saporin in some of the induced media.
Larger scale inductions in 400 mL of the best ex-
presser clones were performed as previously described
(See Additional file 2: Figure S1). In some cases when
several hundred clones were obtained after Pichia trans-
formation, inductions of colony lifts were performed as
described in detail in [30] and shown here in Additional
files 3 and 4: Figures S2-S3.
Protein purifications from P. pastoris culture
Clone 1 construct was purified by a cation Exchange
using Resource S essentially as described [21], with only
low amounts of fusion protein recovered. The clone 4
construct (4KBopt218L-SAPHis6) and the 4KBopt218L-
PE40 supernatants were loaded onto Proteus IMAC kit
(AbD Serotec, Oxford, UK), after concentration of
medium essentially following the manufacturer’s instruc-
tions, except that 25 mM imidazole was used in the
binding buffer during sample loading and 3 washes with
50 mM imidazole in the wash buffer were performed
before elution in the presence of increasing concentra-
tions of imidazole (150, 300, and 500 mM). A first peak
eluted with 150 mM imidazole. Eluates were exchanged
against PBS (pH 7.6) by dialysis and concentrated to
1 mL using Vivaspin 10,000 cutoff concentrators
(Vivascience; Sartorius Stedim Biotech) following centri-
fugation at 5000 g. Samples were analyzed by SDS-
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ting, using SAP-S as a standard.
SDS-PAGE, Western blot and Coomassie-blue staining
SDS-PAGE was performed on 12% polyacrylamide gels.
For Western blot analysis, proteins transferred onto
PVDF membranes (Millipore) were probed with a mouse
anti-His IgG antibody (GE Healthcare), a rabbit anti-
Pseudomonas Exotoxin A serum (Sigma-Aldrich) or a
rabbit anti-saporin anti-serum.
Cell lines
The biological assays were performed on two human
lines of B lymphocytes derived from Burkitt’s lymphoma
and expressing CD22 antigen (Daudi or Ramos cell line)
and two CD22-negative T-lymphoblastoid cell lines
(HSB-2 and H9). Cells were cultured in RPMI 1640
medium (with 40 mg/L folic acid, 2 g/L NaHCO3) (Bio-
chromag) supplemented with 10% FCS, 2 mM L-Glutam-
ine and antibiotics (100 U/mL penicilline and 100 μg/mL
streptomycine-sulphate). Daudi cells were grown in flasks
at 37°C in a 5% CO2 humidified atmosphere.
Binding properties of the fusion proteins to CD22 antigen
The binding characteristics of 4KB128 monoclonal anti-
body and of the 4KB128-derived scFv and rITs for CD22
antigen was assessed using the CD22-positive cell line
Daudi by incubating 3 × 105 cells with increasing con-
centration of purified mAb 4KB128 or scFv (ranging from
10−11 M to 10−5 M) or rITs (from 10−9 M to 10−5 M). Cells
were analyzed for fluorescence on a FACS Caliber flow-
cytometer after a staining with anti-His antibody and a
second incubation with a goat anti mouse-FITC antibody
(Beckman Coulter).
In the competition assay 3 × 105 Daudi cells were pre-
incubated on ice for 20 minutes with increasing amounts
of the purified anti-CD22 mAb 4KB128. Five μg of the
scFv (100 μl) was then added and incubation continued
for one hour on ice. Cells were then stained with anti-
His6-FITC (Miltenyibiotec) and analyzed as described
above. The inhibition of scFv binding was evaluated by
reference to the maximal MFI without competing
4KB128 antibody.
Stability and internalization in target cells
The stability of the anti-CD22 mAb and of the derived
scFv was evaluated by incubation of the antibodies at 37°C
for the same times as in the internalization experiment
(see below). The two antibodies were diluted at concentra-
tions of 0.5 μg/mL (mAb) and 10 μg/mL (scFv) and incu-
bated for up to 60 minutes at 37°C in a water bath. At
each time point the corresponding tube was transferred in
ice and analysed by flow cytometry as described above.Internalization of anti-CD22 mAb and scFv was
assayed on target cell lines Ramos and Daudi. 3 × 105
cells were incubated on ice with 3 μg of scFv or 1 μg of
mAb in a final volume of 100 μl for 1 hour. After two
washes cells were maintained at 37°C in water bath for
0, 2, 5, 10, 20 or 60 minutes. Next, the scFv or mAb
retained on the surface of the cells were detected with
anti-His antibody followed by anti mouse-FITC for the
scFv or with the anti mouse-FITC only for the mAb.
Cytotoxicity assays
Serial dilutions of rITs ranging from 10−8 to 10−13 M
were added to 2.5 × 104 cells seeded in 96-well plate and
maintained in leucine-free RPMI-1640 medium with 2%
fetal calf serum (FCS). After incubation for 48 hours at
37°C, 0.2 μCi of [14C]-leucine or 0.5 μCi of [3H]-leucine
were added. Incorporated radioactive leucine was mea-
sured on a beta counter.
The specific inhibition of 4KB-PE40 IT activity was de-
termined in a competition assay in which Daudi cells
were seeded 2.5 × 104 in a 96-well plate, and incubated
with increasing concentrations of 4KB-PE40 in the pres-
ence or absence of a fixed concentration of the CD22
mAb 4KB128 (10−6 M). After an incubation period of
48 hours at 37°C, [14C]-leucine was added and the incor-
porated radioactivity was measured as described above.
Additional files
Additional file 1: Table S1. Oligonucleotide sequences used to
generate expression plasmids.
Additional file 2: Figure S1. Example of medium and small scale
induction procedures.
Additional file 3: Figure S2. Screening for constructs 7, 8 on plate.
Additional file 4: Figure S3. Screening for construct 9-induced clones
on plate.
Additional file 5: Figure S4. Comparison of secretion yields of Pichia
pastoris clones deriving from constructs 6–9.
Additional file 6: Figure S5. N-terminal histidine tagged fusions
(construct C6, see also Figure 6) were not recognized be the anti-tag
antibody.
Additional file 7: Figure S6. Flow chart representation comparing the
two expression systems tested.
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